

# Gut

*Journal of the British Society of Gastroenterology which  
is a registered charity*

*Editor:* R N Allan

*Technical Editor:* Jackie Foulds

*Review Editor:* Ian Forgacs

*Editorial Assistant:* Michelle Dimler

---

## EDITORIAL BOARD

D Adams

C A Hart

D Rampton

R G Newcombe

M J P Arthur

C J Hawkey

P J Shorvon

*(Statistical adviser)*

I S Benjamin

S G Hubscher

D Swallow

Editor

P Bland

D Kumar

D G Thompson

*British Medical Journal*

I W Booth

M McMahon

B J R Whittle

R Chapman

H O'Connor

G J Dockray

P Quirke

---

## INTERNATIONAL ADVISORY BOARD

B S Anand (USA)

D Y Graham (USA)

R Modigliani (France)

C Arvanitakis (Greece)

J Hansky (Australia)

T Muto (Japan)

G P van Berge Henegouwen  
(Netherlands)

J Heathcote (Canada)

G Paumgartner (Germany)

G Bianchi-Porro (Italy)

R H Hunt (Canada)

D Rachmilewitz (Israel)

A L Blum (Switzerland)

J R Jass (New Zealand)

J Rask-Madsen (Denmark)

M van Blankenstein  
(Netherlands)

S-J Jiang (China)

E Rene (France)

J P Delmont (France)

S J Konturek (Poland)

A Torsoli (Italy)

J Dent (Australia)

S K Lam (Hong Kong)

M M Levine (USA)

J-R Malagelada (Spain)



## CURRENT PRACTICE & CONTROVERSIES IN PAEDIATRIC ENDOSCOPY

Friday, 17 November 1995

GREAT ORMOND STREET  
HOSPITAL FOR SICK CHILDREN NHS TRUST

A one day meeting, under the course directorship of Dr Peter Milla, designed specifically for those interested in child endoscopy. The course will cover basic principles and techniques of upper and lower GI procedures, including the case for sedation or anaesthesia in endoscopy. A two-way audio-visual link will be used to illustrate endoscopy in infants and children, enabling live discussion between endoscopist and audience.

The course fee of £150 includes:  
VAT / tuition / lunch and refreshments / all course materials

For further details please contact:  
Miss Janice Wilkinson, Course Co-ordinator  
KeyMed, KeyMed House, Stock Road  
Southend-on-Sea  
Essex SS2 5QH  
Telephone (01702) 616333 Facsimile (01702) 465677



	PUBLIC'S RATING	DOCTORS RATING
SCREENING FOR BREAST CANCER	2	7
HEART TRANSPLANTS	5	9
HIP REPLACEMENT FOR ELDERLY	7	5
SUPPORT FOR CARERS	6	3
HEALTH EDUCATION	8	4
CHILDHOOD IMMUNISATION	1	1
CARE OFFERED BY GPs	3	2
CARE OF IMMATURE CHILDREN	4	8

# Rationing in Action

It is becoming increasingly obvious that there are not enough resources in the health service to do everything that is possible for all patients. Most doctors accept that some kind of priority setting or rationing of health care is inevitable. But the burning issues are: how should the available resources be distributed? – Is it, for example, more important to finance hip replacements or screening for breast cancer? Who should make these painful decisions? How can public views be accommodated?

*Rationing in Action*, grown out of a conference organised by the *BMJ*, *BMA*, and *King's Fund*, discusses the inevitability of rationing; the challenges; what it means to patients, doctors, and managers; and possible solutions. Written by doctors, managers, politicians, economists, and philosophers, this is an important book for anyone involved in decision making in medicine.

ISBN: 0 7279 0813 8 20 October 1993 160 pages (approx)  
UK £10.95; Overseas £13.00; (BMA Members £9.95; £12.00)

### ORDER FORM

Available from: **BMJ PUBLISHING GROUP**, P.O. Box 295, London WC1H 9TE, medical booksellers or the **BMJ bookshop** in **BMA House**

Please send me \_\_\_\_\_ copy/ies of **RATIONING IN ACTION** Membership No. \_\_\_\_\_

Name \_\_\_\_\_ I enclose \_\_\_\_\_ (Please make cheques payable to **British Medical Journal**)  
(Print Clearly) Debit my credit card  AMERICAN EXPRESS  VISA  MASTERCARD  
(please tick box)

Address \_\_\_\_\_ Card No. \_\_\_\_\_

Exp \_\_\_\_\_

Signature \_\_\_\_\_

Postcode \_\_\_\_\_  Please send me a **BMJ PUBLISHING GROUP CATALOGUE**

metronidazole in triple therapy does not improve the efficacy of treatment, but increases the risk of acquisition of metronidazole resistance.

Determination of bacterial density in the stomach may have some implications for the eradication of the organism. The urea breath tests, which can detect *H pylori* quantitatively, are not routinely available in most units at present. The biopsy dependent rapid urease tests, which are widely used and commercially available, have the potential to determine the bacterial density by measuring the urease activity quantitatively or semi-quantitatively – that is, the greater the number of organisms, the quicker the colour change because of the increased production of ammonia.<sup>8</sup> The currently applied rapid urease tests, based on agar or liquid media, may need modifications for quantitative detection of *H pylori* in the stomach.

H X XIA

C T KEANE

Department of Clinical Microbiology,  
CPL, St James's Hospital,  
Dublin 8, Ireland

C A O'MORAIN

Department of Gastroenterology,  
Meath/Adelaide Hospitals,  
Dublin 8, Ireland

- Berger SA, Gorea A, Moskowitz M, Santo M, Gilat T. Effect of inoculum size on antimicrobial susceptibility of *Helicobacter pylori*. *Eur J Clin Microbiol Infect Dis* 1993; 12: 782–3.
- Haas CE, Nix DE, Schentag JJ. In vitro selection of resistant *Helicobacter pylori*. *Antimicrob Agents Chemother* 1990; 34: 1637–41.
- Editorial. Gastroenterologists in Sydney – histology and helicobacter. *Lancet* 1990; 336: 779–80.
- Xia HX, Daw MA, Sant S, Beattie S, Keane CT, O'Morian CA. Clinical efficacy of triple therapy in *Helicobacter pylori*-associated duodenal ulcer. *Eur J Gastroenterol Hepatol* 1993; 5: 141–4.
- Tytgat GNJ, Noach LA. *H pylori* eradication. In: Hunt RH, Tytgat GNJ, eds. *Helicobacter pylori: Basic Mechanisms to Clinical Care*. Dordrecht: Kluwer Academic, 1994: 550–69.
- Vaira D, Holton J, Cairns S, Polydorou A, Falzon M, Dowsett J, et al. Urease tests for *Campylobacter pylori*: care in interpretation. *J Clin Pathol* 1988; 41: 812–3.
- Beji A, Vincent P, Darchis I, Hussn MO, Cortot A, Leclerc H. Evidence of gastritis with several *Helicobacter pylori* strains. *Lancet* 1989; ii: 1402–3.
- Xia HX, Keane CT, O'Morain CA. Pre-formed urease activity of *Helicobacter pylori* as determined by a viable cell count technique – clinical implications. *J Med Microbiol* 1994; 40: 435–9.

## Reply

EDITOR.—We thank Dr Labenz and coworkers for their thoughtful comments on our study. They have raised basically two questions. The first one is whether a high gastric urease activity as measured by the <sup>14</sup>C-urea breath test is indeed a factor in predicting the effectiveness of eradication with triple therapy? They suggest that other confounding variables might contribute to the strong correlation found. In addition, they wonder whether high urease activity found in the <sup>14</sup>C-urea breath test represents a high bacterial density in the stomach or more severe gastritis.

Concerning the potential confounding

variables, we pointed out in the article that metronidazole resistance of *H pylori* seems to be infrequent in Israel (6% in a preliminary study). We have no data to suggest that compliance with therapy was different in the three patient groups. None of the patients in the study were pretreated with antibiotics or omeprazole in the four weeks before the test. The adverse effect of smoking as reported by Dr Labenz's group is controversial.<sup>1,2</sup> Thus, we have no support for the assumption that these confounding variables might indeed be important factors. We therefore believe that urease activity as measured by <sup>14</sup>C-urea breath test is an important independent variable in predicting the effectiveness of *H pylori* eradication with triple therapy. This is not necessarily true of future therapies, which may be more effective and therefore less dependent on the bacterial load. In addition, we are now studying the effect of some factors mentioned by Dr Labenz *et al*.

The other point is more theoretical. Dr Labenz *et al* question whether the correlation between the <sup>14</sup>C-urea breath test values and density of *H pylori* colonisation as well as the degree of gastritis as reported by other investigators is clinically valid? Also, whether eradication might be more effective in more severe gastritis, which might reflect a stronger immune response? Our data do not permit answers to these theoretical considerations. As pointed out in our paper it is at present not known whether the higher urease activity results only from a higher bacterial load or also from different bacterial strains. This requires further investigation.

We thank Drs Xia, Keane and O'Morain for their valuable comments. We are happy that they agree with our conclusion that a higher bacterial load is of negative predictive value for the success of eradication of *H pylori* with triple therapy. They mentioned two important points: firstly, that resistance, particularly to metronidazole may develop during therapy. We agree, but would point out that the concurrent administration of bismuth salts, as inherent in the triple therapy, attenuates this effect. Secondly, they also suggest that our dose of metronidazole might have been too low, contributing to the overall low eradication rate. Here we have to point out a regrettable error. We gave 750 mg of metronidazole per day – that is, 250 mg thrice daily. This was erroneously printed as 250 mg twice daily. Although 750 mg daily for two weeks is not a high dose, it has been shown to be effective and is less conducive to non-compliance.<sup>3</sup>

Regarding their additional comment, we do not quite agree with their suggestion to use the rapid urease test (of gastric biopsy specimens) as a rough estimate of the gastric bacterial load. Unlike <sup>14</sup>C-urea breath test, which reflects the overall gastric urease activity, the estimation based on a small biopsy sample is much more prone to sampling error.

M MOSHKOWITZ  
F M KONIKOFF  
T GILAT

Department of Gastroenterology,  
Tel-Aviv Medical Centre,  
Ichilov Hospital,  
6 Weizman Street,  
64239 Tel-Aviv, Israel

- Cutler AF, Schubert TT. Patients factors affecting *Helicobacter pylori* eradication with triple therapy. *Am J Gastroenterol* 1993; 88: 505–9.
- Graham D, Malaty H, Evans DG, Klein PD, Adam E. Epidemiology of *Helicobacter pylori* in an asymptomatic population in the United States: effect of age, race and socioeconomic status. *Gastroenterology* 1991; 100: 1495–501.
- Chiba N, Rao BV, Rademaker JW, Hunt RH. Meta-analysis of *Helicobacter pylori* eradication trials. *Am J Gastroenterol* 1992; 87: 1716–27.

## NOTES

### Sir Francis Avery Jones BSG Research Award 1996

Applications are invited by the Education Committee of the British Society of Gastroenterology who will recommend to Council the recipient of the 1996 Award. Applications (**eighteen copies**) should include:

- (1) A manuscript (2 A4 pages *only*) describing the work conducted.
- (2) A bibliography of relevant personal publications.
- (3) An outline of the proposed content of the lecture, including title.
- (4) A written statement confirming that all or a substantial part of the work has been personally conducted in the UK or Eire.

Entrants must be 40 years or less on 31 December 1996 but need not be a member of the BSG. The recipient will be required to deliver a 40 minute lecture at the Spring meeting of the Society in 1996. Applications (**eighteen copies**) should be made to: The Honorary Secretary, BSG, 3 St Andrews Place, London NW1 4LB by 1 December 1995.

### Hopkin's Endoscopy Prize 1996

Entries are invited by the Endoscopy Committee of the British Society of Gastroenterology for the BSG Spring Meeting in Brighton 1996.

The abstract should be confined to two sides of A4 paper but tables and references can be on additional pages. The entry can contain work previously presented/published (please give details).

A cover note should contain the address and post of the entrant.

The winner will give a 20 minute lecture (plus 10 minutes for questions).

The closing date for entries is 6 January 1996 and should be made to: Hopkin's Prize Entry, Dr D M Hellier, Secretary-Endoscopy Committee BSG, Department of Gastroenterology, Princess Margaret Hospital, Okus Road, Swindon SN1 4JU.

# Gut

Journal of the British Society of Gastroenterology  
which is a registered charity

*Gut* publishes original papers, short rapid communications, leading articles, and reviews concerned with all aspects of the scientific basis of diseases of the alimentary tract, liver, and pancreas. Case reports will only be accepted if of exceptional merit. Letters related to articles published in *Gut* or with topics of general professional interest are welcomed. Authors should include the names and addresses of four experts whom the authors consider suitable to peer review their work.

**COMMUNICATIONS** Two copies of the manuscript and figures should be addressed to the Editor, *Gut*, BMA House, Tavistock Square, London WC1H 9JR, UK (tel: 0171 383 6157; fax: 0171 383 6668). Manuscripts should follow the Vancouver conventions (see *BMJ* 1979; i: 532-5. *Gut* 1979; 20: 651-2). They should be in double spaced typewriting on one side of the paper only. The title page should include the name of the author with initials or distinguishing first name only, and the name and address of the hospital or laboratory where the work was performed. **The paper must include a precise summary of the work of less than 200 words, which should be divided into six sections headed background, aims, patients (or subjects), methods, results, and conclusions. Keywords (maximum six) should be included.** Use of abbreviation is discouraged. Short rapid communications should not be more than 10 double spaced A4 pages including references, tables, and figures. These papers will be subject to peer review in the normal way. The interval from acceptance to publication will be much shorter. A covering letter should include a request for the paper to be considered in this category with valid reasons for that request. A separate covering letter signed by all authors must state that the data have not been published elsewhere in whole or in part and that all authors agree to publication in *Gut*. Previous publication in abstract form must be disclosed in a footnote. Papers must not be published elsewhere without prior permission of the Editorial Committee. If requested, authors shall produce the data upon which the manuscript is based for examination by the editor.

**ACKNOWLEDGEMENT OF MANUSCRIPTS** Manuscripts will only be acknowledged if an addressed postcard is enclosed.

**ILLUSTRATIONS** *Photographs* Unmounted photographs on glossy paper should be provided. Illustrations should not be inserted in the text but marked on the back with the figure numbers, title of paper and name of author. All photographs, graphs, diagrams should be referred to as figures and should be numbered consecutively in the text in Arabic numerals. The legends for illustrations should be typed on a separate sheet.

**ETHICS** Ethical aspects will be considered in the assessment of papers (see the Medical Research Council's publications on the ethics of human experimentation, and the World Medical Association's code of ethics, known as the Declaration of Helsinki (see *BMJ* 1964; ii: 177)).

**SI UNITS** All measurements except blood pressure are expressed in SI units. In tables and illustrations values

are given in SI units. For general guidance on the International System of Units and some useful conversion factors, see *The SI for Health Professions* (WHO, 1977). **NB: Such conversion is the responsibility of the author.**

**REFERENCES** These follow the Vancouver system - that is, references numbered consecutively in the text and listed numerically with journal titles abbreviated in the style of *Index Medicus*, *Standard journal article*. List up to six authors, then add *et al*.

**CORRECTIONS** other than printers' errors may be charged to the author.

**REPRINTS** Reprints will be available on payment of the necessary costs; the number of reprints required should be sent to the Publishing Manager on the form provided with the proof.

**NOTICE TO ADVERTISERS** All applications for advertisement space and rates should be addressed to the Advertisement Manager, *Gut*, BMA House, Tavistock Square, London WC1H 9JR.

**NOTICE TO SUBSCRIBERS** *Gut* is published monthly. The annual subscription rates are £191.00 (USA \$309.00). Reduced subscriptions of £79.00 available to trainees for one year (direct only). Orders should be sent to the Subscription Manager, *Gut*, BMA House, Tavistock Square, London WC1H 9JR. Orders can also be placed with any leading subscription agent or bookseller. (For the convenience of readers in the USA subscription orders, with or without payment, can be sent to: *British Medical Journal*, PO Box 408, Franklin, MA 02038, USA. All enquiries, however, must be addressed to the Publisher in London.) Subscribers may pay for their subscriptions by Access, Visa, or American Express by quoting on their order the credit or charge card preferred together with the appropriate personal account number and the expiry date of the card. All overseas copies of the journal are sent by accelerated surface post. If required, full air mail rates and enquiries for single copies already published should be addressed to the Publisher in London.

**COPYRIGHT** © 1995 *Gut*. This publication is copyright under the Berne Convention and the International Copyright Convention. All rights reserved. Apart from any relaxations permitted under national copyright laws, no part of the publication may be reproduced, stored in a retrieval system or transmitted in any form or by any means without the prior permission of the copyright owners. Permission is not, however, required to copy abstracts of papers or articles on condition that a full reference to the source is shown. Multiple copying of the contents of the publication without permission is always illegal.

Second class postage paid, Rahway NJ. Postmaster: send address changes to: *Gut*, c/o Mercury Airfreight International Ltd Inc, 2323 Randolph Avenue, Avenel, NJ 07001, USA. ISSN 0017-5749.